The world’s first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS.
More than 10,000 people aged 65 and over will be asked to take part in a study supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire. The recruitment target is 500. Researchers believe the vaccine could have a major impact on the worldwide fight against the virus, which affects about a billion people worldwide a year with 250,000 to 500,000 annual deaths, mainly in the over-65 age group. Current vaccines are only effective in 30 to 40% of over 65s as the immune system weakens with age and researchers believe the new vaccine could increase this. For those who receive the jab but still get the flu, researchers believe the new vaccine could also reduce the severity and duration of the illness.
It is believed the vaccine will offer a stronger protection against flu because it uses a different mechanism to get the body to protect against the virus. Under the microscope, the flu virus looks like a spherical cushion with lots of pins sticking out of it. The existing flu vaccines use surface proteins that lie on the outside of flu cells – the heads of the pins – to stimulate the body’s immune system to produce disease-fighting antibodies. But as the virus changes each year, so do the surface proteins, haemagglutinin and neuraminidase, meaning the flu vaccine needs to change too.
Global scientists therefore have to predict what each new annual strain of flu will look like. Unfortunately, sometimes by the time the vaccine has been made, the strain of virus that is causing illness has changed, and the vaccine doesn’t work well. The new vaccine is different as it uses the core proteins of the virus –inside the cushion – instead of the surface proteins. These core proteins remain virtually unchanged in all influenza A viruses, giving researchers the opportunity to create vaccines that will work against all of them. Humans get infected by both influenza A and B, but it is influenza A that causes the majority of severe illnesses and deaths.
Crucially, the new vaccine stimulates the immune system to boost influenza-specific T-cells, instead of antibodies, that kill the virus as it tries to spread through the body. Everyone has some influenza-specific T cells already, but numbers of them are often too low to be protective. Previous research found that these T-cells can help fight more than one type of flu virus, and researchers believe this means more people could be protected and the severity and duration of flu may be reduced.
About 10,000 over 65s registered at six GP practices will be asked to take part in the trial in Berkshire and Oxfordshire this winter. This includes 25 people who will be sought for extra blood tests at the university. They will receive the regular, annual immunisation in combination with the new vaccine, which has successfully undergone safety testing in 145 people, or the regular immunisation and a placebo shot, so the two can be compared. Patients will not be told whether they are receiving the new vaccine or placebo.
The vaccine was developed by Oxford University’s Jenner Institute with Vaccitech, a spin-out company from the institute. The study is being sponsored by Vaccitech and managed by the University’s Nuffield Department of Primary Care Health Sciences with support from the NIHR Clinical Research Network Thames Valley and South Midlands, a Department of Health-funded organisation which provides staffing to ensure research studies are run in the health service.
Professor Sarah Gilbert, Professor of Vaccinology at the University and co-founder of Vaccitech, said: ‘Every year, flu in older adults causes serious illness and sometimes death. We want to improve the situation, but in order to do that we need volunteers to help us test a new vaccine. If you are invited to take part, please consider doing so.’
Learn more: World-first trial for universal flu vaccine
The Latest on: Universal flu vaccine
[google_news title=”” keyword=”universal flu vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- New strategy could lead to universal, long-lasting flu shoton May 6, 2024 at 2:35 pm
An experimental influenza vaccine carrying more than 80,000 variations of hemagglutinin antigens caused the immune system of mice and ferrets to respond more strongly to less variable portions of the ...
- Zentek and Triera Biosciences Ltd. Achieve Positive Results Against Avian Influenza (H5N1) using Multivalent Aptamer Technologyon May 6, 2024 at 4:15 am
GUELPH, ON / ACCESSWIRE / /Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has prioritized the ...
- New influenza vaccine strategies aim to enhance protection with T-cell responseson May 5, 2024 at 11:13 pm
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- Unlocking Lifetime Flu Protection: Duke’s Innovative Vaccine Strategyon May 3, 2024 at 5:26 am
Experimental vaccine targets portions of the flu virus that don’t change. Duke researchers have opened a new avenue in the attack against influenza viruses by creating a vaccine that encourages the ...
- No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Keyon May 1, 2024 at 5:00 pm
The two major surface proteins on an influenza virus are called hemagglutinin and neuraminidase ... and human trials would of course be needed before you could rock up to Walgreens and get your ...
- Universal Flu Vaccine May No Longer Be a Long Shoton May 1, 2024 at 5:00 pm
[U.S. Centers for Disease Control] The search for a universal flu vaccine has been long and fraught with false starts and dead ends. For more than five years, Nicholas Heaton, PhD, associate professor ...
- New strategy could lead to universal, long-lasting flu shoton May 1, 2024 at 11:01 am
This new vaccine approach, described May 1 in the journal Science Translational Medicine, is part of a 5-year-old effort to develop a longer-lasting universal flu vaccine that would be able to ...
- Fewer flu shots: Duke researchers working toward a vaccine that could last for yearson May 1, 2024 at 11:01 am
Current annual flu shots offer protection for roughly six months due to mutations in the virus and varying strains that circulate each flu season. Scientists predict a universal flu vaccine could ...
- New Strategy Could Lead to Universal, Long-Lasting Flu Shoton April 30, 2024 at 5:00 pm
Even with vaccines, influenza kills about a half-million people each year around the world. This new vaccine approach, described May 1 in the journal Science Translational Medicine, is part of a ...
- Universal flu vaccine breakthroughon April 29, 2024 at 1:00 pm
Medical scientists are getting closer to developing a universal flu vaccine, which could work on future mutations of the virus.
via Google News and Bing News